文献速递血液净化与透析慢性肾脏病

ASCEND-D试验:达普司他在腹膜透析患者中的疗效与安全性

Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

ASCEND-D III期试验的预设亚组分析纳入340例腹膜透析合并贫血的CKD患者,随机接受达普司他或达依泊汀α治疗,比较血红蛋白变化和主要心血管事件。结果显示两组疗效与安全性相当,支持达普司他在腹膜透析患者中的使用。

要点

  • 达普司他与达依泊汀α在腹膜透析患者中血红蛋白变化无显著差异。
  • 主要心血管事件发生率两组相当,且腹膜透析与血液透析患者间无异质性。
  • 两组不良事件及腹膜炎发生率无差异,支持达普司他用于腹膜透析贫血。

核心结论

  • 在腹膜透析合并贫血的CKD患者中,达普司他与达依泊汀α的疗效和安全性相当,支持其用于该人群贫血治疗。

研究设计与样本

  • ASCEND-D(NCT02879305)为开放标签III期试验的预设亚组分析,纳入340例腹膜透析患者,随机分为达普司他组(n=171)和达依泊汀α组(n=169)。

主要发现

  • 达普司他组和达依泊汀α组血红蛋白平均变化分别为0.38和0.23 g/dL,校正均数差0.15(95%CI -0.04至0.34)。
  • 主要心血管事件首次发生分别为40例(23.4%)和46例(27.2%),HR 0.84(95%CI 0.55-1.28)。
  • 腹膜透析与血液透析患者在上述终点上无异质性。
  • 达普司他组血清铁调素较低,其他铁参数、静脉铁剂用量、输血需求、血压及生活质量无差异。
  • 两组不良事件及腹膜炎发生率无差异。

临床怎么用

  • 腹膜透析合并贫血的CKD患者可考虑使用达普司他替代促红细胞生成素刺激剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD). METHODS: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients). In PD patients, prespecified analyses of the co-primary endpoints of mean change in hemoglobin from baseline to Weeks 28-52 using an ANOVA model and first occurrence of a major cardiovascular event (MACE) using a Cox proportional hazards model were conducted. The secondary endpoints were average monthly intravenous iron dose to Week 52 and treatment-emergent adverse events. Additional post hoc analyses were conducted. RESULTS: Overall, 340 PD patients (daprodustat n = 171, darbepoetin alfa n = 169) were randomized. Mean age was 53.6 years (±14 SD), 55% male, 56% White. For daprodustat and darbepoetin alfa groups respectively, mean change in hemoglobin was 0.38 and 0.23 g/dL [adjusted mean difference 0.15, 95% confidence interval (CI), -0.04, 0.34], and first occurrence of adjudicated MACE occurred in 40 (23.4%) and 46 (27.2%) patients (HR 0.84; 95% CI, 0.55-1.28). No heterogeneity was observed between PD and HD patients for these endpoints in ASCEND-D. Serum hepcidin was lower with daprodustat; there was no difference in other iron parameters, intravenous iron usage, transfusion requirement, blood pressure, or quality of life. There were no differences in adverse events or incidence of peritonitis between the groups. CONCLUSIONS: This subgroup analysis of the ASCEND-D trial demonstrated comparable efficacy and safety of daprodustat versus darbepoetin alfa in PD patients, supporting its use in the treatment of anemia in these patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Dasgupta I, Meadowcroft AM, Bhatt PR, et al. Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2025. PMID: 39817409. doi:10.1093/ndt/gfae273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。